# Jeff Goater

> Jeff Goater is a Series A investor at The Column Group backing Therapeutics and Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [The Column Group](https://shizune.co/investors/profile/the-column-group)
- Location: Boston, United States
- Total investments: 7
- Last investment: Mar 2026
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jeff-goater-a58ba1a
- X (Twitter): https://twitter.com/jeffgoater
- Website: https://x.com/jeffgoater

Jeff Goater is a Series A investor at The Column Group in Boston focused on Therapeutics and Biotechnology. Jeff Goater is the Board Member of Remix Therapeutics. He previously worked at Surface Oncology Inc. as a CEO. Jeff Goater attended the University of Rochester.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 43% |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Health Care | 2 | 29% |
| Life Science | 2 | 29% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Seed | 1 | 14% |
| Series B | 1 | 14% |
| Private Equity | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Series B | Mar 05, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M | Series B | Dec 18, 2025 |  |
| Kenai Therapeutics | Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's. | $82M | Series A | Feb 29, 2024 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Private Equity | Dec 19, 2023 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Venture - Series Unknown | Dec 19, 2023 |  |
| Judo Bio | Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients with both common and rare diseases. | $25M | Seed | Nov 21, 2023 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $60M | Series A | Aug 24, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 5 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 5 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 2 deals together
- [Cure Ventures](https://shizune.co/investors/profile/cure-ventures) — VC Fund, 2 deals together
- [Regeneron Ventures](https://shizune.co/investors/profile/regeneron-ventures) — VC Fund, 2 deals together
- [Alaska Permanent Fund](https://shizune.co/investors/profile/alaska-permanent-fund) — VC Fund, 1 deal together

## About The Column Group

VC Fund · San Francisco, United States

The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.

5 contacts available at The Column Group.

| Name | Title | Profile |
| --- | --- | --- |
| David Goeddel | Managing Partner | https://shizune.co/investors/profile/david-v-goeddel |
| Jeff Goater | Venture Partner | https://shizune.co/investors/profile/dinah-sah-2 |
| Joseph Goldstein | Science Partner | https://shizune.co/investors/profile/joseph-l-goldstein |
| Millie Ray | Partner | https://shizune.co/investors/profile/millie-ray |
| Peter Svennilson | Managing Partner and Founder | https://shizune.co/investors/profile/peter-svennilson |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jeff Goater invest in?

Jeff Goater invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jeff Goater last invest?

The most recent investment recorded for Jeff Goater closed in Mar 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co